Tanyi JL, Stashwick C, Plesa G, Morgan MA, Porter D, Maus MV, June CH: Possible compartmental cytokine release syndrome in a patient with recurrent ovarian cancer after treatment with Mesothelin-targeted CAR-T cells. J Immunother 40(3):104-10 : 2017.
George E, Kim H, Krepler C, Wenz B, Makvandi M, Tanyi JL, Brown E, Zhang R, Brafford P, Jean S, Mach RH, Lu Y, Mills GB, Herlyn M, Morgan M, Zhang X, Soslow R, Drapkin R, Johnson N, Zheng Y, Cotsarelis G, Nathanson KL, Simpkins F: A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. JCI Insight 2(1):e89760 : 2017.
Santoiemma PP, Reyes C, Wang LP, McLane MW, Feldman MD, Tanyi JL, Powell DJ Jr: Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol Oncol 143(1):120-7 : 2016.
Tanyi JL, Haas AR, Beatty GB, Stashwick CJ, O'Hara MH, Morgan MA, Porter DL, Melenhorst JJ, Plesa G, Lacey SF, June CH: Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer (suppl; abstr 5511). Oral presentation, Leveraging the Immuno-Molecular Landscape of Gynecologic Cancers ASCO Annual Meeting, Chicago, IL, J Clin Oncol 34 : 2016.
Haas RA, Plesa G, Torigian D, Moon E, O’Hara M, Beatty G, Tanyi JL, Nelson A, Kerr N, Lacey S, Melenhorst J, Albelda SA, June C: Phase I trial of lentiviral CART-meso cells in progressive malignant pleural mesothelioma (MPM). International Mesothelioma Interest Group 2016 Annual Meeting. Birmingham, UK, : 2016.
Jean S, Li J, Katsaros D, Wubbenhorst B, Maxwell KN, Fishbein L, McLane MW, Benedetto C, Canuto EM, Mitra N, Zhang L, Nathanson KL, Tanyi JL: Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. Oncotarget 7(30):48577-585 : 2016.
Zhang Y, He Q, Hu Z, Feng Y, Fan L, Tang Z, Yuan J, Shan W, Li C, Hu X, Tanyi JL, Fan Y, Huang Q, Montone K, Dang CV, Zhang L: Long noncoding RNA LINP1 regulates repair of DNA double-strand breaks in triple-negative breast cancer. Nat Struct Mol Biol 23(6):522-30 : 2016.
Coukos G, Tanyi J, Kandalaft LE: Opportunities in immunotherapy of ovarian cancer. Ann Oncol (suppl 1):i11-i15 : 2016.
O’Hara M, Stashwick C, Haas AR, Tanyi JL: Mesothelin as a target for chimeric antigen receptor modified T cells as anticancer therapy. Immunotherapy 8(4):449-60 : 2016.
George E, Kima H, Raglanda R, Brown E, Butlerb L, Giladb O, Tanyi JL, Zhang R, Krepler C, Leed R, Morgan MA, Burger RA, Ko EM, Kim SH, Herlyn M and Simpkins F: Capitalizing on synthetic lethality in homologous recombination-deficient high-grade serous ovarian cancers with a novel ATR inhibitor. Poster on the 47th Annual Meeting of Women’s Cancer, SGO, San Diego, CA, : 2016.